Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Iruplinalkib in ALK/ROS1-Positive NSCLC
NCT04641754Phase 2Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of iruplinalkib in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Primary endpoint: Confirmed Objective Response Rate (IRC) at 18 weeks. Status: unknown.
02
Drugs
iruplinalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04641754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641754.